Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STAR COMBO PHARMA LIMITED Board/Management Information 2018

Jun 20, 2018

65746_rns_2018-06-20_bd6f1be5-1a67-411f-8e8c-53d3b8e29910.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [145 x 46] intentionally omitted <==

Star Combo Pharma Limited ACN 615 728 375 of 171 - 177 Woodpark Rd, Smithfield, NSW 2164 www.starcombo.com.au

21 June 2018

Company Announcements ASX Limited 20 Bridge Street SYDNEY NSW 2000

ASX Announcement Appointment of Non-executive Director

Star Combo Pharma Limited (ASX: S66) today announced the appointment of Dr Ziye Sui as a non-executive director. Dr Sui M.D. Ph.D. is currently the Vice President of Lepu Medical Technology (Beijing) Co. Limited, a Chinese listed company owning approximately 11.8% of the issued capital of S66. She is also the CEO of Lepu Hushengtang Internet Technology Co. Limited and is currently a director of Hainan MSD Pharmaceutical Co. Limited.

Dr Sui has extensive knowledge and experience in the production, regulation, sales & marketing of medical devices internationally with a particular emphasis on China.

Star Combo Chairman, Richard Allely, said: “We welcome Dr Sui to Star Combo and look forward to her contribution. Dr Sui’s breadth and depth of experience, particularly in the wholesale & retail of pharmaceutical products in China will be an asset to the Board.”

For further information: Su Zhang CEO Star Combo Pharma Limited +61 2 9756 6555 [email protected]